1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Aleafia Health Inc.
  6. News
  7. Summary
    AH   CA01444Q1046

ALEAFIA HEALTH INC.

(AH)
  Report
Delayed Toronto Stock Exchange  -  10:29 2022-08-19 am EDT
0.0650 CAD   -7.14%
08/11Aleafia Health Q1 EPS Loss $0.01 Vs Profit $0.02 Year Ago, Net Revenue Rises 13%; Reaffirms Full-Year Guidance
MT
08/11TRANSCRIPT : Aleafia Health Inc., Q2 2022 Earnings Call, Aug 11, 2022
CI
08/11Aleafia Health Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Aleafia Health : Audited Financial Statement

07/02/2022 | 01:13pm EDT

ALEAFIA HEALTH INC.

CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in Canadian dollars)

For the Fifteen Months Ended March 31, 2022 and

Twelve Months Ended December 31, 2020

MANAGEMENT'S RESPONSIBILITY

To the Shareholders of Aleafia Health Inc.:

The accompanying consolidated financial statements of Aleafia Health Inc. and its subsidiaries (the "Company") were prepared by management, which is responsible for the integrity and fairness of the information presented, including the many amounts that out of necessity are based on estimates and judgements. These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards.

In fulfilling its responsibilities, management designs and maintains the necessary accounting systems and related internal controls to provide reasonable assurance that transactions are authorized, assets are safeguarded, and financial records are properly maintained to provide reliable information for the preparation of these consolidated financial statements.

The Board of Directors oversees the responsibilities of management for financial reporting through an Audit Committee, which is composed entirely of independent directors. This Audit Committee reviews the consolidated financial statements and recommends them to the Board of Directors for approval. They meet regularly with management to review internal control procedures and advise directors on accounting matters and financial reporting issues.

"Tricia Symmes"

"Matthew Sale"

Patricia Symmes-Rizakos

Matthew Sale

Chief Executive Officer

Chief Financial Officer

2

INDEPENDENT AUDITOR'S REPORT

To the Shareholders of

Aleafia Health, Inc.

Opinion

We have audited the accompanying consolidated financial statements of Aleafia Health Inc. and its subsidiaries (collectively, the "Company"), which comprise the consolidated statement of financial position as at March 31, 2022 and the consolidated statements of loss and comprehensive loss, changes in shareholders' equity and cash flows for the 15-month period then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as at March 31, 2022, and its consolidated financial performance and cash flows for the 15-month period then ended in accordance with International Financial Reporting Standards ("IFRS").

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements for the 15-month period ended March 31, 2022. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. The key audit matters to be communicated in our auditors' report are as follows:

Impairment of goodwill, intangible assets and property, plant and equipment

We draw attention to Notes 3(b), 7 and 8 to the consolidated financial statements. Goodwill and indefinite lived intangible assets are not amortized, but are reviewed for impairment annually or more frequently when events or changes in circumstances indicate that the carrying amount of a cash generating unit ("CGU") exceeds its recoverable amount. Intangible assets with finite lives and property, plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying amount exceeds its recoverable amount. During the 15-month period ended March 31, 2022, the Company recorded an impairment charge of $11.3 million for goodwill, $53.1 million for intangible assets and $28.8 million for property, plant and equipment. Estimating the recoverable amount of CGUs and intangible assets is complex and is subject to significant judgments in relation to assumptions used by management. Significant assumptions used by management to estimate the recoverable amount include growth and discount rates, as well as future revenues, gross margins and recoverable values.

We identified the evaluation of the impairment of goodwill and intangible assets as a key audit matter as significant auditor judgment and the involvement of professionals with specialized skill and knowledge

3001 N. Rocky Point Dr. East Suite 200 Tampa, Florida 33607 813.367.3527

2 | P a g e

were required to evaluate the Company's methods and use of estimates, assumptions and judgments in estimating the recoverable amount of the Company's CGUs.

Our audit response to the key audit matter was as follows:

  • We obtained an understanding of the controls and control activities in place related to the determination and management's review of significant assumptions used in the calculation.
  • We performed sensitivity testing to consider the impact of changes in certain assumptions on the estimate of recoverable amount.
  • With the assistance of a valuation specialist:
    1. We evaluated whether the valuation techniques used in estimating the recoverable amounts were appropriate.
    2. We compared the discount rate used to the weighted average cost of capital and evaluated the reasonableness based on publicly available information for comparable companies.
    3. We compared growth rates used by management to historical information, approved budgets, the Company's production capacity, as well as industry standards.

Valuation of biological assets and cannabis inventory

We draw attention to Notes 3(a), 13 and 14 to the consolidated financial statements. Biological assets are measured at fair value less cost to sell at the stage of completion. The Company values inventories of harvested bulk cannabis and finished goods at the lower of cost and net realizable value.

In estimating the fair value of biological assets, management is required to make a number of estimates, including estimating the stage of growth of the cannabis up to the point of harvest, average yield per plant, harvesting costs, selling costs, selling price, and the allocation of indirect costs, which form part of the standard cost per gram to complete production. In calculating final inventory values, management is required to determine an estimate of spoiled or expired inventory and compares the inventory cost to estimated net realizable value.

We identified measurement of the fair value of biological assets and net realizable value of cannabis inventory as key audit matters as a high degree of auditor judgment was required to evaluate the significant assumptions and estimates made by management.

Our audit response to the key audit matter was as follows:

  • We performed sensitivity analyses over the Company's significant assumptions used to determine the fair value of biological assets to assess the impact of changes in those assumptions on the Company's determination of fair value.
  • We tested the stage of growth by observing the plants at year-end.
  • We tested the average expected yield per plant by comparing actual results of the current year to historical results of operations.
  • We tested the average selling price per gram by comparing to estimates used by management to actual sales prices per gram in actual sales transaction during and subsequent to year-end.
  • We also tested the net realizable value of inventory by comparing the carrying value of inventory to the prices earned from sales transactions near and subsequent to year-end.

3 | P a g e

Emphasis of Matter - Restated Comparative Information

We draw attention to note 23 to the consolidated financial statements, which explains that certain comparative information presented for the year ended December 31, 2020 has been restated. Our opinion is not modified in respect of this matter.

The consolidated financial statements of the Company for the year ended December 31, 2020, excluding the adjustments that were applied to restate certain comparative information as described in note 23, were audited by another auditor who expressed an unqualified opinion on those statements on March 24, 2021.

As part of our audit of the consolidated financial statements for the period ended March 31, 2022, we also audited the adjustments that were applied to restate certain comparative information for the year ended December 31, 2020 as described in note 23. In our opinion, such adjustments are appropriate and have been properly applied.

Other Information

Management is responsible for the other information, which comprises the information included in the Company's Management's Discussion and Analysis to be filed with the relevant Canadian securities commissions.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion on thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

We obtained Management's Discussion and Analysis prior to the date of this auditor's report. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with IFRS, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going-concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Aleafia Health Inc. published this content on 02 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 July 2022 17:12:07 UTC.


© Publicnow 2022
All news about ALEAFIA HEALTH INC.
08/11Aleafia Health Q1 EPS Loss $0.01 Vs Profit $0.02 Year Ago, Net Revenue Rises 13%; Reaff..
MT
08/11TRANSCRIPT : Aleafia Health Inc., Q2 2022 Earnings Call, Aug 11, 2022
CI
08/11Aleafia Health Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022
CI
08/11Aleafia Health Announces $12.0 Million Total Net Revenue in First Quarter, Representing..
GL
08/11Aleafia Health Announces $12.0 Million Total Net Revenue in First Quarter, Representing..
AQ
08/04Aleafia Health to Announce Fiscal Year 2023 First Quarter Results
GL
08/04Aleafia Health to Announce Fiscal Year 2023 First Quarter Results
AQ
07/06Aleafia Health Downgraded to Underperform at Raymond James
MT
07/05ALEAFIA HEALTH : Annual Management Discussion and Analysis
PU
07/02ALEAFIA HEALTH : Audited Financial Statement
PU
More news
Analyst Recommendations on ALEAFIA HEALTH INC.
More recommendations
Financials
Sales 2023 60,6 M 46,9 M 46,9 M
Net income 2023 - - -
Net Debt 2023 - - -
P/E ratio 2023 -1,17x
Yield 2023 -
Capitalization 28,2 M 21,8 M 21,8 M
Capi. / Sales 2023 0,47x
Capi. / Sales 2024 0,51x
Nbr of Employees 211
Free-Float 98,5%
Chart ALEAFIA HEALTH INC.
Duration : Period :
Aleafia Health Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALEAFIA HEALTH INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 0,07 CAD
Average target price 0,17 CAD
Spread / Average Target 143%
EPS Revisions
Managers and Directors
Tricia Symmes Chief Executive Officer
Matt Sale Chief Financial Officer
Mark J. Sandler Chairman
Michael Verbora Chief Medical Officer
Luciano Galasso Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ALEAFIA HEALTH INC.-48.15%22
CVS HEALTH CORPORATION0.47%136 062
HCA HEALTHCARE, INC.-16.30%61 722
LABORATORY CORPORATION OF AMERICA HOLDINGS-20.30%22 638
QUEST DIAGNOSTICS-21.41%15 854
REDE D'OR SÃO LUIZ S.A.-20.14%13 651